Oryzon’s CEO Carlos Buesa said the company has completed a capital increase and secured an anchor investor agreement with Cofides to support its forthcoming clinical milestones. The financing bolsters Oryzon’s balance sheet, reduces funding risk for its drug pipeline, and signals investor confidence in the company’s near‑term clinical progress. Oryzon, its CEO Carlos Buesa, and the public investor entity Cofides. Oryzon will deploy the proceeds to advance its clinical programs and may pursue additional partnerships or further funding rounds as milestones are met. Oryzon’s CEO Carlos Buesa announced that the biotech firm has closed a capital increase and brought in Cofides as an anchor investor for any future equity raises. The move is intended to strengthen the company’s financial position as it advances toward key clinical trial readouts. By locking in a long‑term investor, Oryzon aims to reduce funding uncertainty and signal confidence to the market.
INTELLIGENCE
Social Pulse
AI estimate · not scraped